Literature DB >> 15902730

Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells.

Wen-Dong Li1, Mi-Juan Wang, Fang Ding, Da-Li Yin, Zhi-Hua Liu.   

Abstract

AIM: To investigate if non-peptidic small molecular inhibitors of the p53-HDM2 interaction could restore p53 function and kill tumor cells.
METHODS: A series of non-peptidic small HDM2 inhibitors were designed by computer-aided model and synthesized by chemical method. Syl-155 was one of these inhibitors. Cytotoxic effect of syl-155 on three tumor cell lines with various states of p53, HT1080 (wild-type p53), KYSE510 (mutant p53), MG63 (p53 deficiency) was evaluated by MTT assay, Western blot and flow cytometry.
RESULTS: Syl-155 stimulated the accumulation of p53 and p21 protein in HT1080 cells expressing wild-type p53, but not in KYSE510 and MG63 cells. Consequently, syl-155 induced cell cycle arrest and apoptosis in HT1080 cells.
CONCLUSION: Non-peptidic small molecular inhibitors of the p53-HDM2 interaction show promise in treatment of tumors expressing wild-type p53.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902730      PMCID: PMC4305661          DOI: 10.3748/wjg.v11.i19.2927

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Binding of an inhibitor of the p53/MDM2 interaction to MDM2.

Authors:  Sara J Duncan; Matthew A Cooper; Dudley H Williams
Journal:  Chem Commun (Camb)       Date:  2003-02-07       Impact factor: 6.222

Review 2.  The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?

Authors:  S M Picksley; D P Lane
Journal:  Bioessays       Date:  1993-10       Impact factor: 4.345

3.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

4.  Caspase activity is required for commitment to Fas-mediated apoptosis.

Authors:  V L Longthorne; G T Williams
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.

Authors:  L Chen; S Agrawal; W Zhou; R Zhang; J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

7.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

8.  The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Authors:  Jianhua Zhao; Mijuan Wang; Jie Chen; Aiping Luo; Xiuqin Wang; Min Wu; Dali Yin; Zhihua Liu
Journal:  Cancer Lett       Date:  2002-09-08       Impact factor: 8.679

9.  A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

Authors:  P Chène; J Fuchs; J Bohn; C García-Echeverría; P Furet; D Fabbro
Journal:  J Mol Biol       Date:  2000-05-26       Impact factor: 5.469

Review 10.  Functions of the MDM2 oncoprotein.

Authors:  D A Freedman; L Wu; A J Levine
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

View more
  8 in total

Review 1.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 2.  Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets.

Authors:  Dingding Shi; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

3.  Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.

Authors:  Jason A Clement; Jirouta Kitagaki; Yili Yang; Carrie J Saucedo; Barry R O'Keefe; Allan M Weissman; Tawnya C McKee; James B McMahon
Journal:  Bioorg Med Chem       Date:  2008-10-14       Impact factor: 3.641

4.  Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.

Authors:  Jirouta Kitagaki; Keli K Agama; Yves Pommier; Yili Yang; Allan M Weissman
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

5.  N-Terminal Domain of Fragile Histidine Triad Exerts Potent Cytotoxic Effect in HT1080 Cells and Increases Doxorubicin Cytotoxicity.

Authors:  Ameneh Eslamparast; Reza Abbasgholizadeh; Seyed Nasser Ostad; Mehdi Gharghabi; Mohammad Hossein Ghahremani
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

6.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

Review 7.  Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.

Authors:  Ainsley Mike Antao; Apoorvi Tyagi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

Review 8.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.